You are here: Industry Insights > Liver cancer

News List

Against Liver Cancer, Statins Helps Novel Liver Cancer Drug Development Yuntian/PharmaSources
April 20, 2023
Statins help to improve liver cancer and have been confirmed by a large number of clinical and scientific trials.
Immune Drug Combination Therapies for Liver Cancer: Analysis of the Clinical Studies of the Two Approved and Two First-line Drug Combinations PharmaSources/Yuntian
May 31, 2021
Liver cancer has recently drawn much attention by a Chinese movie star Ng Man-tat who died of liver cancer and the National Liver Day on Mar. 18.
Sirtex Medical and Grand Pharmaceutical Group Limited receive NDA approval of SIR-Spheres® Y-90 resin microspheres in China from the National Medical Products Administration prnasia
February 11, 2022
Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today with its shareholder, Grand Pharmaceutical Group Limited, that SIR-Spheres® Y-90 resin microspheres...
Pre-Op Treatment May Be Advance Against Deadly Liver Cancers drugs.com
January 28, 2022
When delivering a liver cancer diagnosis, Dr. Thomas Marron pulls no punches: "Liver cancer is one of the deadliest cancers," he tells patients.
Innovative phase 2 trial targets advanced liver cancer pharmatimes
January 25, 2022
The UCL study will evaluate the safety and effectiveness of MTL-CEBPA in combination with second line standard of care sorafenib versus the use of sorafenib in isolation。
111, Inc. Enters into Strategic Cooperation Agreement with Zelgen to Develop a New Management Platform for Liver Cancer Patients in China prnasia
August 04, 2021
111, Inc., a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced a strategic cooperation agreement with Suzhou Zelgen Biopharmaceuticals Co., Ltd., ...
Q BioMed's Uttroside-B Receives Orphan Drug Designation for Liver Cancer americanpharmaceuticalreview
February 03, 2021
Q BioMed announced the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B, a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most ...
Roche’s Tecentriq/Avastin combo improves survival in liver cancer pharmatimes
January 14, 2021
Roche is planning to present updated data confirming that its immunotherapy combination, consisting of Tecentriq (atezolizumab) and Avastin (bevacizumab), improves overall survival (OS) in patients with a type of liver cancer.
Stellar Results from Kintor's GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40% prnasia
December 10, 2020
On December 9, 2020, Kintor Pharmaceutical Limited is pleased to announce that the Group has collected positive data in phase II clinical trials of combination therapy of ALK-1 (GT90001) antibody and PD-1 (Nivolumab or Opdivo) antibody for the second ...
Roche obtains EC approval for Tecentriq/Avastin to treat liver cancer pharmaceutical-technology
November 05, 2020
Roche has obtained approval from the European Commission for Tecentriq (atezolizumab) and Avastin (bevacizumab) combination to treat adult patients with advanced or unresectable hepatocellular carcinoma (HCC).

Previous page 1 2 3 4 5 Next page